Numares. |Precision Diagnostics.

2

Locations: Houston, Texas;
Regensburg, Germany

60+

Employees of medical and
scientific disciplines

2004

Founded as a spin-off of
Regensburg University in Regensburg, Germany

3.5 M

Tests performed globally

Mastering Metabolite Constellations. |For Precision Diagnostics.

Numares is an innovative diagnostics company. We focus on the discovery, development and commercialization of diagnostic tests, using metabolite constellations to solve unmet health care needs not addressed by single biomarker-based medicine.

Our diagnostic tests are based on the interpretation of multiple biomarkers that precisely pinpoint relevant data related to organ function. With these next-generation metabolite constellations, we develop non-invasive diagnostic tests designed to provide more precise information than the current standard tests.

Company Milestones

2021

Exclusive license agreement with Oxford University

2021

FDA 510(k) submission for the AXINON^®System, an NMR platform for metabolomics-based, AI-driven diagnostics

2021

Numares and Bruker Corporation sign agreement to enable advanced metabolomics-based clinical diagnostics

2019

Numares begins collaborating with Mayo Clinic Laboratories to develop new diagnostic tests

2018

Numares completes another financing round

2018

Start of pan-European multicenter study PARASOL to evaluate metabolite constellations to detect kidney allograft rejection

2017

Launch of AXINON^® renalTX-SCORE^®-U100: first metabolomics IVD test for allograft rejection diagnostics after kidney transplantation

2017

Collaboration with Oxford University to develop a multiple sclerosis diagnostic test

2016

1 million performed analyses

2016

Numares completes another financing round

2015

Launch of CE-marked IVD test AXINON^® lipoFIT^®-S100 for comprehensive NMR-based lipoprotein profiling

2014

600,000 performed analyses

2014

Successful completion of studies on kidney transplantation

2014

Cooperation with a German laboratory network: commissioning a test system for lipoprotein profiling

2013

200,000 performed analyses

2013

Bulk order from a U.S. laboratory chain: installation of multiple test systems for lipoprotein profiling

2013

Successful certification of Numares according to EN ISO 13485: 2012 as a manufacturer of in-vitro diagnostics (IVD)

2010

100,000 performed analyses

2009

Certification as per EN ISO 13485:2003

2005

Measurements in large studies, such as GRAPHIC and KORA

2004

First patent for the determination of lipoproteins in body fluids (lipoprotein profiling)

Leadership

“AXINON^® combines flexibility, personalization and high-tech - ideal conditions to make diagnostics available for everyone, to minimize health care costs and maximize shareholder value.”

Florian Voss

Executive Board, Chief Executive Officer

“Our AXINON^® platform combines software engineering and AI/machine learning with NMR technology. This gives us the rare opportunity to address multiple metabolic markers, constellations of markers and, ultimately, diseases, using a single technology platform. Because of this capability, the AXINON^® platform provides a wide range of applications from life sciences to routine diagnostics to personalized diagnostics.”

Andreas Wolf

Chief Technical Officer

“Although our AXINON^® IVD System requires only minimal operator interaction, we provide our clients with the best support – beyond set-up and maintenance.”

Dr. Lutz Niggl

Head of Service

Supervisory Board

Volker Pfahlert, PhD

- Chairman, Supervisory Board
- Former CEO, Numares Health
- Previously with Roche and McKinsey

Kathy L. Bates, MBA

- Former Sr. Director of Partnership, Mayo Clinic
- Previously with OncoSpire Genomics and Roche

Gregory F. Heath, PhD

- Former General Manager of Diagnostics, Illumina, Inc.
- Former Sr. Vice President of Molecular Business, Roche Diagnostics

Jorg Neermann, PhD

- Board of Directors, Immunic
- Former CEO, Curexsys GmbH
- Former Partner, Life Sciences Partners

Gerhard Ries, PhD

- CEO and Co-Founder, Kineo Finance
- Former Managing Partner and Co-Founder, BioMedPartners
- Former Business Development Manager, Novartis and McKinsey

Helge Luetzen

- Sr. Investment Manager, Mayfair

Name	Purpose	Lifetime	Type	Provider
_gcl_au	Used by Google AdSense to experiment with advertisement efficiency.	3 months	HTML	Google
AMP_TOKEN	Contains a token that can be used to retrieve a Client ID from AMP Client ID service. Other possible values indicate opt-out, request in progress or an error retrieving a Client ID from AMP Client ID service.	1 year	HTML	Google
_dc_gtm_--property-id--	Used by DoubleClick (Google Tag Manager) to help identify the visitors by either age, gender or interests.	2 years	HTML	Google

“AXINON® combines flexibility, personalization and high-tech - ideal conditions to make diagnostics available for everyone, to minimize health care costs and maximize shareholder value.”

Florian Voss

Andreas Wolf

“Although our AXINON® IVD System requires only minimal operator interaction, we provide our clients with the best support – beyond set-up and maintenance.”

Dr. Lutz Niggl

Volker Pfahlert, PhD

Kathy L. Bates, MBA

Gregory F. Heath, PhD

Jorg Neermann, PhD

Gerhard Ries, PhD

Helge Luetzen

“AXINON^® combines flexibility, personalization and high-tech - ideal conditions to make diagnostics available for everyone, to minimize health care costs and maximize shareholder value.”

“Although our AXINON^® IVD System requires only minimal operator interaction, we provide our clients with the best support – beyond set-up and maintenance.”